News

January 22, 2018January 22, 2018

Pulmonary Fibrosis Foundation Expands National Care Center Network

The Pulmonary Fibrosis Foundation (PFF) plans to expand its national PFF Care Center Network to further serve the community of patients, caregivers and loved ones affected by pulmonary fibrosis (PF). The ... Read more

January 19, 2018January 19, 2018

Eiger BioPharmaceuticals Discontinues Development of Ubenimex in PAH After Disappointing Results

News, Pulmonary Hypertension

Eiger BioPharmaceuticals will discontinue the development of ubenimex as a therapy for pulmonary arterial hypertension (PAH) due to disappointing results in the Phase 2 LIBERTY clinical trial. The treatment failed to ... Read more

January 17, 2018January 17, 2018

Health Canada Issues Safety Warning on Pulmonary Fibrosis Therapy Ofev

Idiopathic Pulmonary Fibrosis, News

Reports of liver injuries stemming from the pulmonary fibrosis therapy Ofev (nintedanib), including a fatality, have prompted Health Canada to issue a safety warning about it to medical professionals. The regulatory agency said ... Read more

January 16, 2018January 16, 2018

Fasenra Approved in EU for Treatment of Severe Eosinophilic Asthma

Asthma, News

The European Commission has approved Fasenra (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma. The approval, announced by therapy developer AstraZeneca and its global research and development arm, MedImmune, follows FDA approval of ... Read more

January 12, 2018January 12, 2018

European Union Approves Orkambi Use for Children 6-11 Years Old

Cystic Fibrosis, News

The European Commission has granted Vertex Pharmaceuticals an extension of the marketing authorization for Orkambi (lumacaftor/ivacaftor) to include children 6-11 years old who have cystic fibrosis (CF) caused by two copies ... Read more

January 11, 2018January 11, 2018

Bellerophon Enrolls First Patient in Study of INOpulse to Treat PH Linked to Interstitial Lung Disease

Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

A Phase 2b clinical study evaluating INOpulse as a treatment for pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) enrolled the first patient, Bellerophon Therapeutics has announced. Patients with ... Read more

January 10, 2018January 10, 2018

Insurance Coverage Affects Treatment Given Small-cell Lung Cancer Patients in US, Study Shows

Lung Cancer, News

Insurance status for people in the U.S. with non-metastatic small-cell lung cancer (SCLC) can determine both the type of treatment they are given and their likelihood of survival, a new study ... Read more

January 9, 2018January 9, 2018

Proteostasis’ Planned Trial of Triple Combo CF Therapy Supported By Advocacy Groups in US, Europe

Cystic Fibrosis, News

The drug development arms of two leading cystic fibrosis (CF) organizations, one in the U.S. and one in Europe, have endorsed Proteostasis Therapeutics’ coming trial of a triple combination therapy ... Read more

January 8, 2018January 8, 2018

Tackling Asthma’s Genetic Causes May Yield New Therapies and ID Higher-risk Patients, Yale Study Says

Asthma, News

More insight into the genetic causes of asthma may open new therapeutic avenues and help identify people at higher risk of developing the disease, say researchers at the Yale School of Public ... Read more

January 5, 2018January 5, 2018

US Continues Its Decades-long Drop in Cancer Mortality Rates

Lung Cancer, News

Cancer mortality rates in the United States have continued to steadily decline, with 2.4 million fewer cancer-related deaths reported in 2015 than in 1991, when rates started to decrease. This represents ... Read more